Shenzhen Kangtai Biological Products (300601) Fundamentals 2026 — P/E 177.6x, Revenue Analysis | SniperIQ
Shenzhen Kangtai Biological Products (300601) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥13.8B, trading at ¥12.34 on the SHZ. This SniperIQ fundamentals page covers Shenzhen Kangtai Biological Products's valuation (P/E 177.6x, P/B 1.4x), profitability (net margin 3.1%), revenue (¥2.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen Kangtai Biological Products's market cap?
Shenzhen Kangtai Biological Products (300601) has a market capitalization of approximately ¥13.8B, trading at ¥12.34 on the SHZ. Market cap moves with the live share price.
What is Shenzhen Kangtai Biological Products's P/E ratio?
Shenzhen Kangtai Biological Products's trailing twelve-month P/E ratio is 177.6x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen Kangtai Biological Products?
Shenzhen Kangtai Biological Products runs a net profit margin of 3.1%, a gross margin of 74.1%, and an operating margin of 2.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen Kangtai Biological Products generate?
Shenzhen Kangtai Biological Products reported revenue of ¥2.7B for fiscal year 2025, with net income of ¥70M and earnings per share (EPS) of 0.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen Kangtai Biological Products pay a dividend?
Shenzhen Kangtai Biological Products offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen Kangtai Biological Products financially healthy?
Shenzhen Kangtai Biological Products carries a debt-to-equity ratio of 0.20x and a current ratio of 2.87x, with a market beta of 0.68. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen Kangtai Biological Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen Kangtai Biological Products (300601) the key facts are: market cap ¥13.8B, P/E 177.6x, revenue ¥2.7B, 52-week range 10.7-21.12. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen Kangtai Biological Products's full fundamentals live
Get Shenzhen Kangtai Biological Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.